INSIGHT: FDA Exclusivities Add Incentives to Covid-19 Drug Race

Published May 4, 2020

There is currently a race to find a treatment for the Covid-19 pandemic. Certainly, there are good will and reputational incentives to be the first to find a cure, but there are fairly substantial economic incentives as well. Food and Drug Administration (FDA) offers exclusivities for the first new approved active ingredient molecule, as well as a new treatment for an old molecule.

Related Stories